H.C. Wainwright lowered the firm’s price target on Renalytix to $5 from $8 and keeps a Buy rating on the shares post the fiscal Q2 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RNLX:
- Renalytix reports Q2 EPS (14c), consensus (14c)
- Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
- Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
- Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Renalytix announces $20.3M private placement